This site is intended for health professionals only
Tuesday 18 December 2018
Share |

Latest News

European Commission approval for self-administration of Xolair® across all indications

Monday 17th December 2018
Novartis has announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.
With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
Thu, 29 Nov 2018
Researchers investigated cardiac function in relation to diagnosed OSA and self-reported snoring from data available through UK Biobank
Thu, 29 Nov 2018
In the EU, regorafenib is indicated for treatment of adult patients with advanced unresectable hepatocellular carcinoma who have been previously treated with sorafenib
Thu, 29 Nov 2018
The discovery could potentially accelerate early diagnosis, speed up drug discovery and lead to advancements in personalised medicines
Wed, 28 Nov 2018
Cryoablation represents a potential new weapon in the arsenal against breast cancer
Wed, 28 Nov 2018
Incidence of infections were estimated to be lower when using Acticoat compared with other silver dressings
Wed, 28 Nov 2018
Data from the ALTA trial showed sustained systemic and intracranial efficacy results and a manageable safety profile, leading to the longest progression-free survival and overall survival reported in this setting
Tue, 27 Nov 2018
NHS on track to make £300m in savings after adalimumab deals